Abstract
A highly invasive Du145-III subline was isolated by three successive passages of the parental Du145 prostate tumor cell line (Du145-P) through a Boyden chamber with matrigel-coated membrane support. Du145-III cells showed great invasion potential based on their increased ability to spread/migrate and enhanced expression/secretion of the matrix metalloproteinase 9 (MMP9). Du145-III cells exerted vasculogenic mimicry (VM) properties, reminiscent of endothelial cell characteristics and expressed elevated levels of cancer stem cell (CSC) markers, including Nanog, Sox2, CD44 and ABCG2 and ability to self-renew. Of prominence, MMP9 was required for the induction of VM and for increased stemness in Du145-III cells. Using Du145-III as a model, the effects of dietary flavonoids, luteolin and quercetin, were evaluated on stemness and invasion capacity of Du145-III cells in relation to JNK signaling pathway activation. These flavonoids depressed the malignancy of highly invasive Du145-III cells, VM, anchorage-independent spheroid formation and expression of certain CSC markers. Since luteolin and quercetin were able to target CSC cells and prevent cancer cell invasiveness, may serve as potential anti-angiogenesis and anti-metastasis agents.
Prostate cancer, one of the most common cancers afflicting males in developed countries, is the third leading cause of cancer mortality in men (1). This type of cancer is often fatal once it spreads to other parts of the body, particularly to lung and bone tissues. Currently, there is not an effective and reliable therapy for metastatic prostate cancer with a definitive survival benefit. Towards this aim, it is imperative to develop more efficacious and robust therapeutic options. The inhibition of tumor invasion and metastatic processes appears to be a valuable approach toward cancer therapy.
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that function in extracellular matrix remodeling and at least 28 MMP genes have been identified (2). MMPs are instrumental in triggering tumor progression and in advancing metastasis in invasive cancers (3). It is considered that the remodeling of extracellular matrix facilitates tumor cell migration and provides the requisite microenvironment for tumor growth. MMPs possess additional important functions, which include modulation of growth factors and cell surface receptors (4). The collective and multifaceted activities of MMPs are deemed crucial for cancer progression. Enhanced expression and activation of key MMPs compared to normal tissues is a hallmark of almost all human cancers (3), suggesting that MMPs play a vital role in the initiation and progression of metastasis. MMPs are considered to facilitate the penetration of prostate cancer cells into the blood and lymph vessels and to mediate angiogenesis (5, 6). This could be attributed to MMP-mediated release of angiogenic factors, such as the vascular endothelial growth factor (VEGF) (7). Previous studies have documented an association between the elevated expression of MMPs (including MMP2, MMP7, MMP9, MMP15 and MMP26) and the progression of malignant prostate carcinomas (8). Accordingly, manipulation of secretion, synthesis and/or the activity of MMPs in cancers may inhibit tumor progression.
Recently, an alternative mechanism for the progression of malignancy was suggested wherein a vascular-like structure derived from tumor cells integrates with the host's endothelial system. The study of Maniotis et al. (9) in highly aggressive and genetically dysregulated melanoma cells, was the first to describe this novel and fascinating phenomenon that the authors termed as, “vasculogenic mimicry” (VM). VM is considered as a structure that can mimic vascular networks and has been equated to angiogenesis (10). VM has since been detected in several different types of cancers, such as head and neck, breast and prostate cancer (9, 11, 12). Folkman et al. showed that existence of tumor cells in the lining of vessels could significantly promote cancer metastasis (13) and that the phenomenon correlates positively with poor prognosis of patients (14, 15). The high plasticity of cancer cells forming VM highlights the existence of a dedifferentiation process in cancer cells. Cancer stem cells (CSCs) are able to undergo dedifferentiation and have received substantive research focus (16). CSCs may represent causal factors in cancer recurrence, providing an alternative paradigm to cancer therapy.
Accordingly, recent findings highlight the possibility that CSCs or tumor-initiating cells in certain cancer types could be linked to resistance against conventional chemotherapy (17). These cells exhibit unique properties such as self-renewal and differentiation into diverse cell types that constitute the tumor (18). CSCs in tumor cell lines share similar markers as those of their corresponding counterparts in original primary tumors (19). CSCs were identified based on their enriched expression of the cell surface markers CD44, CD133, ITGA2B1, KRT5/KRT14, KRT8/KRT18 and ABCG2 (20-22). In addition, genes used to score for “stemness”, such as Oct4, Sox2, Nes and Nanog, could be markers for the identification of CSCs (23, 24). It is noteworthy that in prostate cancer more than one stem cell type can be present (25). CSCs markers might also represent a valuable tool in the detection of primary cancer cells in micrometastasis. Proteins MMP2 and MMP9 play a pivotal role in tumor initiation, development, metastasis and neovascularization/angiogenesis (6, 26, 27). However, the relationship between MMP2 and MMP9 levels and the presence of CSC markers (such as CD44 and CD133) is poorly defined and warrants further study (22).
Flavonoids are natural antioxidants and are almost ubiquitous in their distribution in the plant kingdom, particularly in most edible plants and medicinal herbs (28, 29). They are integral constituents of the human diet (28) and their dietary intake could be significant in vegetarian populations. Flavonoids are able to disrupt cellular and molecular events associated with tumor growth and metastasis. Substantial evidence indicates that certain dietary flavonoids, like luteolin and quercetin, can inhibit the growth and proliferation of tumor cells (30) and inhibit angiogenesis (31, 32). Luteolin (Lu) and quercetin (Qu) can suppress metastasis of A431 cells by attenuating the Akt/mTOR/c-Myc signaling pathway leading to a decreased expression of the ribosomal protein S12 (RPS12) (33). Furthermore, reversed epithelial-mesenchymal transition (EMT) to reduce MMP secretion by Lu and Qu exert inhibition of migration and invasion abilities in A431 cells (34). Since MMPs' function is central in tumor development, Lu and Qu inhibitory activity can potentially mitigate tumor progression, invasion, metastasis and tumor-associated angiogenesis (3, 4, 7). Lu and Qu can also attenuate the phosphorylation of SRC and CTTN in A431-III cells, resulting in suppression of MMP secretion and impairment of invadopodia that are associated with degradation of the extracellular matrix in cancer invasiveness and metastasis (35). Since tumor growth and metastasis are dependent on angiogenesis, cancer therapeutic strategies have increasingly focused on targeting different aspects of angiogenesis. Previous reports have drawn attention to the ability of dietary flavonoids to attenuate angiogenic stimulants (36, 37).
Recent findings indicate that CSCs characterized by uncontrolled self-renewal can produce progeny cancer cells, which may explain cancer relapses and represent a critical target for cancer prevention. Zhang and coworkers established that genistein, a dietary isoflavonoid may inhibit the stemness of prostate cancer cells via the Sonic Hedgehog (SHH)–GLI1 pathway (38). The anthocyanin-containing baked purple-fleshed potato (PP) extracts (PA) may contribute to colon CSCs reduction and decrease the rate of tumor incidence in vivo by suppression of the Wnt/β-catenin signaling pathway and increase of mitochondria-mediated apoptosis (39). Quercetin treatment reduced pluripotency, migration and adhesion of human teratocarcinoma cell line (40). Epigallocatechin-3-gallate (EGCG), accompanied by Qu treatment, was shown to inhibit prostate cancer stem cell characteristics and invasion (41). In these cells, EGCG was shown to regulate the SSH pathway and Nanog transcription factor of pluripotency (42). However, efforts to evaluate the efficacy of the above bioactive compounds on CSCs and decipher their potential effects in cancer are scanty. Towards this aim, CSCs were identified in Du145 prostate cancer cells and the relationship between CSCs and metastasis was characterized. Additionally, by using the above cell line model, the impact of Lu and Qu treatment on CSCs on cancer metastatis and progression was assessed.
Materials and Methods
Reagents. Quercetin was purchased from Nacalai Tesque (Kyoto, Japan). Luteolin was purchased from Extrasynthese (Genay, France). RPMI-1640 and fetal calf serum (FBS) were obtained from GIBCO (Grand Island, NY, USA). MMP9, Nanog and non-specific siRNAs were purchased from Invitrogen (Carlsbad, CA, USA). Anti-β-actin antibody was obtained from Sigma (St. Louis, MO, USA). Anti-CD44 and anti-ABCG2 antibodies were procured from Santa Cruz (Santa Cruz, CA, USA). Anti-Nanog, JNK, pJNK and Jun antibodies were acquired from Cell Signaling (Danvers, MA, USA). Anti-JUN antibody was obtained from Abcam (Cambridge, MA, USA). Forward and reverse PCR primers were purchased from Purigo Biotech (Taipei, Taiwan). Growth factor-reduced EHS matrigel was acquired from BD (Franklin Lake, NJ, USA). Enhanced chemiluminescence reagent (ECL) was obtained from Amersham (Buckinghamshire, UK). SP600125 was acquired from Merck (Whitehouse Station, NJ, USA).
Cell culture. The Du145 tumor cell line was obtained from ATCC. The cells were cultured as monolayer in an atmosphere of 5% CO2 at 37°C and grown in tissue-culture flasks containing RPMI-1640 supplemented with 10% FBS.
In vitro invasion assay and isolation of highly invasive Du145 tumor cells. In vitro invasiveness was studied as previously described (43). Briefly, 24-well transwell units with polycarbonate filters (8-μm pore size; BD) were coated with 0.1 mL of 0.8 mg/mL Englebreth-Holm-Swarm (EHS) sarcoma tumor extract (BD) for 1 h at 25°C. These filters were then air-dried at room temperature to form a thin and continuous layer on the filter surface. The lower compartment contained RPMI-1640 medium with 10% FBS as a chemoattractant. Du145-P cells (5×104) were placed in the upper compartment and incubated with or without flavonoids at 37°C for 48 h. Following incubation, the filters were fixed with 3% glutaraldehyde in PBS and stained with crystal violet. Cells on the upper surface of the filter were removed by wiping with a cotton swab; penetrating cells through the matrigel were counted using a microscope (200×). Two independent experiments were performed and each treatment was performed in triplicate.
To obtain cells with higher invasion capacity, the small inserts were removed, and the cells that settled onto the culture flask were continuously cultured until they reached 60% confluence. The cells were then sub-cultured (designated as Du145-I). The Du145-I cells were reapplied to the Boyden chamber, and the experiments described above were repeated until Du145-III cells were obtained (43).
Preparation of cell lysates. Lu and Qu treated and untreated Du145-P and Du145-III cells were harvested and washed three times with PBS and lysed in Gold lysis buffer as previously described (44). The insoluble material was collected by centrifugation at 14,000xg for 20 min at 4°C.
Detection and characterization of MMPs. MMPs secreted from tumor cells were characterized using gelatin zymography (45). Samples from conditioned media were subjected to electrophoresis on 8% SDS-polyacrylamide gel (SDS-PAGE) containing 0.1% porcine gelatin. The volume of each sample analyzed was normalized by its corresponding cell number. After electrophoresis, the gels were washed twice for 30 min with 2.5% Triton X-100 and then twice with reaction buffer (50 mM Tris-HCl, pH 8.0, containing 5 mM CaCl2, 0.02% NaN3) for 30 min. The gels were then incubated in reaction buffer at 37°C for 48 h.
In vitro wound-healing assay. Du145-P and Du145-III cells were plated onto six-well culture plates in RPMI-1640 containing 10% FBS (2×106 cells/well). After 24 h, the cell layer was wounded by manual scratching with a pipette tip, washed with PBS and then incubated at 37°C with or without 20 μM Lu or Qu. The cells were photographed at 0 and 24 h after wounding using phase contrast microscopy and an Olympus IX70 camera.
In vitro capillary formation assay. 80 μL of EHS matrigel was added to each well of a 48-well plate and allowed to solidify for 3 h at 37°C. Following matrigel solidification, Du145-P and Du145-III cells (1.5×104) were added to each well in serum-free medium. Four hours later, when the cells had adhered to the matrigel, Lu or Qu was added. The cells were incubated for 24 h at 37°C. The capillary formation of Du145-P and Du145-III cells was detected by photography.
Western blot. The cell lysate samples were dissolved in 5× sample buffer, boiled for 5 min and then separated in 10% SDS-PAGE gels. The nitrocellulose membranes used to transfer the proteins, were blocked in PBS containing 5% BSA for 1 h at room temperature. The membrane blots were then incubated with primary antibody overnight at 4°C, washed with TBST (Tris-buffered saline with Tween-20) as previously described (44) and then incubated with secondary antibody conjugated with horseradish peroxidase. The membranes were again washed with TBST and the immunoreactive protein bands were detected using ECL reagents exposed on Fujifilm. The relative signal intensity of ECL signals on X-ray film was quantified by Image J software analysis (NIH).
PCR amplification. Total RNA was isolated using the PureLink RNA Mini Kit (Invitrogen) and was reverse transcribed by the MMLV High Performance Reverse Transcriptase kit (Epicentre, Madison, WI, USA). The PCR program was performed for 20-40 cycles by denaturing at 94°C for 30 s, annealing at 55-60°C for 30 s, and extension at 72°C for 30-60 s. The annealing temperature, extension time and reaction cycles were adjusted for different genes. The PCR products were separated on 2% agarose gels stained with SYBR safe DNA stain (Invitrogen) and visualized by UV exposure.
Transfection of siRNA. Du145-P and Du145-III cells (2.5×105 cells) were allowed to adhere in 60-mm culture dishes for 24 h. In order to prepare the transfection mixture, 6 uL of Lipofectamine 2000 reagent (Invitrogen) was thoroughly mixed with 300 μL serum-free RPMI-1640 medium and incubated for 5 min at room temperature. Then, 6 μL of siRNA was added to 300 μL serum-free RPMI-1640 medium and thoroughly mixed. The siRNA mixture was then combined with the diluted Lipofectamine 2000, gently mixed and incubated for 20 min at room temperature. The complexes were then added to the 60 mm culture dishes containing 2.4 mL serum-free RPMI-1640 medium for 24 h. All assays were performed 48 h after transfection.
Spheroid assay. Du145-P and Du145-III cells were suspended in serum-free DMEM/F12 media supplemented with 0.2× B27 lacking Vitamin A (Invitrogen), EGF at 10 ng/mL, 1× antibiotics and antimycotic (GIBCO). The cells were then plated in 24-well ultra-low-attachment plates (Corning) at a density of 4×103 cells/well. After two weeks, the plates were analyzed for tumor- sphere formation and quantified using an inverted microscope.
Statistical analysis. Statistical significance between groups was determined using an unpaired Student's t-test. A p<0.05 was considered significant for all tests. The results from three to six independent experiments are expressed as the mean±SEM.
Results
Isolation of Du145-III from Du145 prostate cancer cells. Although CSCs in prostate tumors have been previously detected, the relationship between stemness and malignancy of these cells has not been clearly shown. We speculated that a small population of stem-like cells in Du145 might overexpress MMPs and show metastatic potential. To investigate this possibility, we isolated a highly invasive prostate cancer subline (Du145-III) from the parental Du145-P tumor cell line by three successive passages through a Boyden chamber with EHS matrigel-coated membrane support. After three rounds of selection, we observed that Du145-I, Du145-II and Du145-III expressed higher mRNA and secreted successively greater quantities of MMP9 than Du145-P (Figure 1A). We also observed that cell-to-cell adhesion of Du145-III cells decreased and dispersal of Du145-III cells increased compared to Du145-P cells. Additionally, Du145-III cells showed a tendency to have protruding filopodia, while Du145-P cells grew more cohesively (Figure 1B).
To probe the differences in cell migratory capacity and invasiveness between Du145-P and Du145-I, -II and -III cells, we performed in vitro wound-healing and invasion assays respectively. The results showed significant differences in the ability of Du145-P cells to migrate to the open area at 24 h compared to that of Du145-III cells. We found that Du145-III cells nearly closed the gap (Figure 1C) and the invasive ability exhibited by them was greater than that of Du145-P cells (Figure 1D).
Du145-III cells exhibit vasculogenic mimicry and intermix into the HUVEC network. Du145-III cells were found to secrete increased quantities of MMP9, compared to Du145-P cells (Figure 1A). Since MMP9 expression is related to angiogenesis, an in vitro capillary formation assay was employed in order to examine whether cells with increased MMP9 expression exhibit VM characteristics. This method has been previously used to study vessel formation by endothelial cells and to gauge the angiogenic capacity of tumor cells. Du145-P and sublines when cultured on matrigel, organize into tubular networks resembling capillaries. However, the extent of capillary formation showed a gradual increase from parental Du145 cells to sublines Du145-I, -II and -III (Figure 2A).
Formation of VM could be exhibited by stem-like cells that can differentiate and function as endothelial cells. To confirm that Du145-III cells can mimic an endothelial cell phenotype, HUVEC and Du145-III cells were cultured simultaneously in matrigel. Du145-III and HUVEC cells were transfected with double-strand RNA (dsRNA) conjugated with FITC or Alexa Fluor® Red respectively. As shown in Figure 2B, Du145-III and HUVEC cells adhered together and formed a network. To ascertain that Du145-III subline contains cells with an endothelial phenotype, we stained Du145-III in matrigel with isolectin B4 (IB4), which is a dye specific for endothelial cells. The results show that a network of capillaries was stained by IB4 (Figure 2C) and indicates that Du145-III might differentiate into or resemble endothelial cells.
Du145-III cells show increased self-renewal ability and expression of CSC markers compared to Du145-P cells. We examined whether Du145-III cells exhibited stem cell-like properties. Du145-P and Du145-III cells were plated in stem cell culture medium in ultra-low binding 24-well plates at a density of 4×103 cells/well. Both Du145-P and Du145-III cells were able to generate non-adherent spheroids separated from each other. Figure 3A shows anchorage-independent spheroids formed by Du145-P and Du145-III cells within 14 days culture. Du145-III cells formed larger spheroids and in greater numbers compared to Du145-P cells, suggesting that Du145-III cells possess higher quantities of stem-like cells than Du145-P cells.
It is well-known that CSCs express pluripotent markers, such as Nanog, Oct4 and Sox2 and progenitor markers, such as CD44, CD133, KRT18 and ABCG2. The expression of these markers in Du145-III cells was analyzed and compared to the corresponding levels in Du145-P cells. Our results showed that Du145-III subline contain more stem-like cells, since it expressed more protein levels of CD44, ABCG2, Sox2 and Nanog markers compared to the Du145-P cells (Figure 3B). There were no significant differences between the parental and subline cells regarding the levels of KRT18, Oct4 and Sox9 protein markers while CD133 marker was not detected at the protein level.
MMP9 is involved in the self-renewal and VM in Du145-III cells. MMPs play crucial roles in both tumor angiogenesis and vasculogenesis. Therefore, the potential role of MMP9 in VM was assessed by knocking-down MMP9 levels in Du145-III cells. Transfection of siRNA against MMP9 in Du145-III cells effectively reduced the levels of both mRNA and protein levels of MMP9 (Figure 4A). The inhibition of MMP9 reasonably inhibited both cell motility and invasiveness (Figure 4B and C). MMP9 siRNA-transfected Du145-III cells were also found to possess greatly attenuated capillary formation (Figure 4D). MMPs have been confirmed to be critical in maintaining stemness (46, 47). In this study, decreased MMP9 expression was found to greatly diminish the number and volume of spheroids in Du145-III cells (Figure 4E). These results indicate that MMP9 is necessary for the induction of VM and increased stemness in Du145-III cells.
JNK signaling pathway is associated with the maintenance of stemness and metastatic potential in Du145-III cells. Recent studies have demonstrated that JNK plays a pivotal role in the maintenance of self-renewal and tumorigenicity (48, 49), governs stemness (48, 50) and is involved in the expression and secretion of MMP9 (51). Therefore, JNK phosphorylation activity might be required to maintain the stemness of Du145-III cells. Western blot analysis revealed that the levels of phosphorylated JNK and JUN protein in Du145-III cells are more than in Du145-P cells (Figure 5A). In order to associate the enhanced activity of JNK in Du145-III cells with an increased metastatic potential or stemness, Du145-III cells were treated with a JNK specific inhibitor (30 μM, SP600125). Inhibition of JNK activity led to a decrease of MMP9 secretion, cellular motility, and invasiveness in Du145-III cells (Figure 5B-D). Furthermore, SP600125 treatment disrupted capillary formation in Du145-III cells (Figure 5E) and decreased the expression of CSC markers, Sox2 and Nanog but did not change the expression of CD44 and ABCG2 markers compared to untreated cells (Figure 5F). Inhibition of JNK also reduced self-renewal ability and diminished sphere-forming capacity of Du145-III cells (Figure 5G). These results suggest that elevated JNK activity in Du145-III cells might associated with stemness. We then examined whether JNK could impair self-renewal capability by affecting pluripotent transcription factors. Nanog expression is reported to be regulated by Sox2 and Oct4 (52). Thus, Nanog may be a downstream regulator of stemness. A Nanog-specific siRNA was used (Figure 5H) to knockdown Nanog in Du145-III which resulted in fewer and smaller spheroids, as shown in Figure 5I. Cumulatively, these data suggest that activation of JNK signaling pathway can increase motility and invasiveness in Du145-III cells via regulation of Nanog expression.
Luteolin and Quercetin inhibit VM, metastatic potential, and stemness via JNK activity in Du145-III cells. We next attempted to validate our hypothesis that Lu and Qu could inhibit JNK kinase activity and decrease MMP9 secretion, CSC marker expression and disrupt sphere-formation. A dramatic difference was found in the extent of MMP9 secretion between Du145-P and Du145-III cells. We have recently reported that A431-III cells shows high migratory ability of A431-III cells partly due to elevated expression of MMP9 and Snail, as evidenced by siRNA knockdown of these two genes (44). Therefore, the relatively higher levels of MMP9 secretion by Du145-III cells observed in the current study could lead to enhanced cell migration. We have previously established that out of Lu and Qu dietary flavonoids used in this study, are the two most active compounds against MMP secretion in cancer cells and therefore could interfere with tumor invasion, metastasis and VM stimulation.
In order to assess the effects of Lu or Qu treatment on metastasis and VM, Du145-III cells were treated with 20 μM Lu or Qu for 24 h and MMP9 levels were analyzed by RT-PCR and zymography. The expression and secretion of MMP9 were repressed by treatments with Lu or Qu, as shown in Figure 6A. Interestingly, the flavonoid treated cells displayed a significant delay in Du145-III migration, depressed Du145-III invasion (Figure 6B) and significantly inhibited capillary formation, as shown in Figure 6C. Additionally, Du145-III cells treated with 20 μM Lu or Qu for 24 h showed markedly reduced expression of CD44, ABCG2, Sox2 and Nanog compared to untreated cells (Figure 6D, left panel). Finally, the effect of Lu or Qu treatment on anchorage-independent spheroid formation was assessed in Du145-III cells. Treatment with Lu or Qu dramatically reduced the number and volume of spheroids in cultured Du145-III cells (Figure 6D, right panel).
The results obtained from our previous experiments revealed that JNK played a crucial role in the acquisition of stemness and metastatic potential in Du145-III cells and that Lu and Qu were also involved in the regulation of these capabilities in Du145-III cells. The results led us to speculate that Lu and Qu may regulate the JNK signaling pathway. As shown in Figure 6E, Lu and Qu inhibit phosphorylation of JNK and JUN. However, the total protein levels of JNK and JUN were not altered. These data suggest that both Lu and Qu inhibit the metastatic potential, VM, and stemness of CSCs through via modulation of the JNK signaling pathway.
Discussion
Recent evidence links CSCs with cancer metastasis and relapse (18, 53). In order to explore the causal role of CSCs in metastasis, several CSC isolation methods have been developed (54). Yu and coworkers utilized the Boyden chamber apparatus to isolate potential CSCs based on their invasive properties. They showed that an invasive population within the U87 glioma cell line had high levels of CSCs (54). Additional evidence has shown the presence of CSCs in various human cancers (55-57). Prostate tumors have been reported to contain approximately 0.1% CSCs (58). In this study, a highly invasive prostate cancer Du145-III subline was isolated from its parental Du145-P cell line by three passages through the EHS matrigel-coated Boyden chamber apparatus. Du145-III cells were demonstrated to have increased levels of MMP9, enhanced cell migration and high levels of invasion compared to Du145-P, which prompted us to investigate VM in Du145-III cells.
In this study, VM was clearly observable in Du145-P and Du145 sublines by in vitro capillary formation assays but Du145-III cells however showed more complete capillaries and network structure formation. Interestingly, we identified a possible connection between VM and endothelial cells since Du145-III and HUVEC developed a network structure collectively. It is particularly noteworthy that staining with isolectin B4 of Du145-III cells revealed within the formed-capillaries the presence of endothelial cell subpopulations. Therefore, the structure and the expression of endothelial markers of these capillaries need to be characterized to gain insights into this finding in the further. Recent studies have proposed the involvement of CSCs in this differentiation process in prostate cancer cells (59). However, there is currently limited evidence supporting the functional importance of VM in prostate cancer. Confirmation along these lines is a key aim in the field of human prostate cancer research. Data accrued suggest that Du145-III cells may display a phenotype resembling endothelial cells via de-differentiation and that VM might be mediated by CSCs (60).
The Du145-III subline exhibits increased expression of MMP9 and stem cell markers and enhanced capillary and spheroid formation. This prompted us to hypothesize that there is a positive regulatory loop between MMP9 and CSCs. We premise that MMP9 might play an important role in promoting VM and spheroid formation. Recent studies have demonstrated that the inhibition of JNK activity triggers the loss of self-renewal capability and reduces CSC markers such as Sox2, NES, and BMI1(49). In our system, we also detected that JNK inhibition reduced Sox2 and Nanog expression and impaired self-renewal capacity. The impact of MMP9 on spheroid formation, as we have established above, is one of our most substantial and noteworthy findings. We also conjecture that Nanog expression decrement accounts for this observed reduction.
Indeed, the knockdown of Nanog could have synergized with the action of EGCG in impairing spheroid formation in CSCs (41). In our system, we found that the knockdown of Nanog reduced both spheroid number and volume. These data strongly indicated that the inactivation of JNK attenuated metastatic potential and stemness via regulation of MMP9 and suppressed the self-renewal capability of Du145-III via Nanog. A similar result caused by the knockdown of MMP9 and of Nanog might be a major finding that clarifies the interrelationship between CSCs and MMP9.
We have previously shown (28) that Lu and Qu are the two most potent flavonoid modulators of oncogenesis inhibition and that they exhibited a variety of anticancer effects, such as cell growth and kinase activity inhibition, apoptosis induction, differentiation, suppression of MMP expression, reduction in tumor cell adhesion, and impairment of cancer invasive behavior, metastasis and angiogenesis in a wide spectrum of tumor cells (29, 30, 61, 62). Additionally, we detected that the pharmacologic effects of Lu and Qu extended to other realms of anticancer activity, including the suppression and secretion of MMP9. Lu and Qu also suppressed the migratory and invasive potential and VM in Du145-III cells. These profound actions suggest that these two dietary flavonoids impair the metastatic potential and VM of Du145-III cells.
CSCs promote tumor onset and metastasis and are often resistant to conventional therapies. Therefore, we further explored the potential effects of plant flavonoids on the expression of diverse markers intricately linked with tumor formation and metastasis in CSCs from the Du145-III subline. We found that Lu and Qu lowered the expression of CSC markers CD44, ABCG2, Sox2 and Nanog and substantively attenuated cancer stem cell associated spheroid formation. Lu and Qu inhibited the JNK signaling pathway, which explains their effects on stemness, VM and metastatic potential. Previous studies have indicated that JNK kinase activity plays an important role in maintaining the stemness of glioblastoma and other cells (48, 49).
We may consider that one of the potentially successful approaches to the treatment and management of cancer would involve anticancer therapy that judiciously impairs differentiated cancer cell functions and significantly diminishes the CSC population (63). Our Du145-III cell model appears to be promising in that it establishes a rapid, sensitive and reliable method with the preamble of enriching and obtaining highly invasive cancer cells amenable for studying the relationship between CSCs and metastasis. A comparison of Du145-P and Du145-III cells provides a useful experimental strategy to characterize signaling pathways and genes that are relevant to the regulation of stemness, cell migration, and invasion. Our future studies will involve establishing animal models with subcutaneous or orthotopic implants of prostate cancer Du145-III cells, as previously described (64), to further comprehend the intricacies of the JNK signaling pathway in vivo. CSCs, not the remaining tumor cells, possess the capacity to initiate a tumor that resembles the heterogeneity and characteristics of the original tumor when transplanted in vivo (50). Using this animal model, we can identify candidate molecules involved in the JNK signaling pathway. In addition, we wish to learn whether Lu, Qu, and SP600125 suppress the JNK pathway in vivo.
Our present data suggest that Lu and Qu are promising and prospective candidates that function as anti-CSC and anti-metastasis agents. Together with the JNK inhibitor SP600125, they may provide a new approach for therapeutic treatment in the future. In addition, our selective Du145-III prostate cancer cell model system could serve as a useful tool to develop and establish effective therapies that target CSCs.
Acknowledgements
This work was supported in part by grants from the National Science Council of Taiwan (NSC 102-2311-B-002 -046 -MY3 to G.D.C.); Ministry of Science and Technology, Taiwan, R.O.C. (104-2311-B-038-001 to C.H.C.) and the Taiwan Academia Sinica Thematic Project (AS-96-TPB06 to M.T.L.)
Footnotes
↵* These Authors contributed equally to this study.
- Received August 31, 2016.
- Revision received September 30, 2016.
- Accepted October 3, 2016.
- Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved